MX2022002196A - Composición de liberación retardada de niclosamida y uso antiviral de la misma. - Google Patents

Composición de liberación retardada de niclosamida y uso antiviral de la misma.

Info

Publication number
MX2022002196A
MX2022002196A MX2022002196A MX2022002196A MX2022002196A MX 2022002196 A MX2022002196 A MX 2022002196A MX 2022002196 A MX2022002196 A MX 2022002196A MX 2022002196 A MX2022002196 A MX 2022002196A MX 2022002196 A MX2022002196 A MX 2022002196A
Authority
MX
Mexico
Prior art keywords
delayed
niclosamide
release composition
antiviral use
relates
Prior art date
Application number
MX2022002196A
Other languages
English (en)
Inventor
Donghwan Kim
Minsuk Lee
Bokki Kang
Sanghan Park
Original Assignee
Daewoong Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200101136A external-priority patent/KR102486564B1/ko
Application filed by Daewoong Therapeutics Inc filed Critical Daewoong Therapeutics Inc
Publication of MX2022002196A publication Critical patent/MX2022002196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para la prevención o tratamiento de infecciones por coronavirus, que comprende una composición de liberación retardada de niclosamida o una sal farmacéuticamente aceptable de la misma, y un método para prevenir o tratar infecciones por coronavirus mediante el uso de la misma.
MX2022002196A 2019-08-23 2020-08-21 Composición de liberación retardada de niclosamida y uso antiviral de la misma. MX2022002196A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190103824 2019-08-23
KR20200037560 2020-03-27
KR20200044237 2020-04-10
KR1020200101136A KR102486564B1 (ko) 2019-08-23 2020-08-12 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
PCT/KR2020/011196 WO2021040337A1 (ko) 2019-08-23 2020-08-21 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도

Publications (1)

Publication Number Publication Date
MX2022002196A true MX2022002196A (es) 2022-05-24

Family

ID=74683596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002196A MX2022002196A (es) 2019-08-23 2020-08-21 Composición de liberación retardada de niclosamida y uso antiviral de la misma.

Country Status (5)

Country Link
US (1) US20230000803A1 (es)
EP (1) EP4019002A4 (es)
BR (1) BR112022003434A2 (es)
MX (1) MX2022002196A (es)
WO (1) WO2021040337A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
US20230190684A1 (en) * 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
WO2022204397A1 (en) * 2021-03-26 2022-09-29 First Wave Biopharma Treatment of long haulers syndrome with niclosamide
KR20240032430A (ko) * 2022-09-02 2024-03-12 주식회사 스카이테라퓨틱스 니클로사미드의 신규 염, 이의 분자회합체 및 이를 포함하는 약학 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343810B (en) * 2003-05-28 2011-06-21 Nat Health Research Institutes A pharmaceutical composition for inhibiting coronavirus
CN101007170A (zh) * 2007-01-25 2007-08-01 上海交通大学 包虫病药物缓释制剂的制备方法
CN101317564A (zh) * 2008-06-11 2008-12-10 熊海波 一种环保型氯硝柳胺缓释块及其制作方法
US20150065526A1 (en) * 2013-09-05 2015-03-05 Emory University Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
CN107811967B (zh) * 2016-09-09 2021-08-24 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) 抗寄生虫药物原位固化缓释注射剂及其制备方法
CN108935457A (zh) * 2018-07-26 2018-12-07 广西田园生化股份有限公司 蜂蜡在可控释农药中的应用及以蜂蜡为基质制备控释农药的方法

Also Published As

Publication number Publication date
WO2021040337A1 (ko) 2021-03-04
EP4019002A1 (en) 2022-06-29
EP4019002A4 (en) 2023-03-01
BR112022003434A2 (pt) 2022-05-24
US20230000803A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2019009443A (es) Metodos para tratar la influenza.
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
MX2019012884A (es) Terapia de combinacion.
PH12017501421A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021010144A (es) Formulaciones farmaceuticas.
MX2021002322A (es) Nuevos metodos.
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
MX2022003945A (es) Metodo para tratar vih con cabotegravir y rilpivirina.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
MX2019014784A (es) Tratamiento para la migra?a.